Dr. Lianhua Ye 叶联华
Chief Physician
Department of Thoracic Surgery, Yunnan Cancer Hospital, Kunming
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive thoracic surgery and comprehensive treatment of lung cancer.
Dr. Ye holds a PhD and serves as Chief Physician and doctoral supervisor. Recognized as a leading medical talent in Yunnan Province, Dr. Ye leads provincial innovation teams in lung cancer prevention and thoracic surgery. Research focuses on minimally invasive thoracic surgery. Dr. Ye has led or participated in 16 research projects, including National Natural Science Foundation grants, and received multiple provincial science and technology awards.
Professional roles
- Council Member, Youth Council of China Anti-Cancer Association
- Vice Chair, Youth Committee of Thoracic and Cardiovascular Surgery Branch, Yunnan Medical Association
- Youth Committee Member, Lung Cancer Professional Committee, China Anti-Cancer Association
- Member, Thoracic Surgery Branch, Yunnan Medical Doctor Association
Name order: in Chinese the family name comes first (Ye Lianhua). Papers usually list the name as Lianhua Ye or Ye L.
Selected publications
61 papers on PubMed matched by name and affiliation; 31 as first or senior author since 2016. Most recent first- or senior-author papers:
- ANZ J Surg, 2026 (senior author): Surgical Patterns and Survival Outcomes in Young Women With Early-Stage Lung Adenocarcinoma: A Population-Based Analysis. PubMed 42457639
- Cancer Cell Int, 2026 (senior author): An integrative framework combining Mendelian randomization, single-cell profiling, and experimental validation identifies FTMT as a mitochondrial-immune regulator in non-small cell lung cancer. PubMed 42304365
- J Cardiothorac Surg, 2026 (senior author): Primary posterior mediastinal epithelioid angiosarcoma presenting as epigastric pain: long-term survival achieved via multimodal salvage therapy after early recurrence. PubMed 42032638
- Sci Rep, 2026 (senior author): The role of BLZF1 in lung adenocarcinoma and its value as a diagnostic and prognostic biomarker. PubMed 41820452
- Mol Med Rep, 2026 (senior author): PDX1 in human cancers: Molecular mechanisms, dual roles and clinical implications (Review). PubMed 41574674
- Front Immunol, 2025 (senior author): CT-based nomogram for predicting EGFR mutation status in ground-glass nodules of lung adenocarcinoma. PubMed 41357203
- J Cardiothorac Surg, 2025 (senior author): RBM15 is a novel prognostic biomarker and correlates with immune cell infiltration in lung adenocarcinoma. PubMed 41137052
- Discov Oncol, 2025 (senior author): Development and validation of a hypoxia-immune-based microenvironment gene signature for predicting survival in non-small cell lung cancer. PubMed 40759816
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion